Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index

Journal of the National Cancer Institute

Volumn 108, Issue 2, 2016, Pages

  Chlebowski, Rowan T ^a   Anderson, Garnet L ^b   Aragaki, Aaron K ^b   Prentice, Ross ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BLACK PERSON; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CAUCASIAN; CLINICAL TRIAL (TOPIC); ETHNIC DIFFERENCE; FEMALE; HAZARD RATIO; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; ADVERSE EFFECTS; AFRICAN AMERICAN; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; ECONOMICS; EPIDEMIOLOGY; ESTROGEN THERAPY; ETHNOLOGY; FINANCIAL MANAGEMENT; INCIDENCE; META ANALYSIS; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; OBESITY; ODDS RATIO; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STATISTICS AND NUMERICAL DATA; UNITED STATES; WOMEN'S HEALTH;

AFRICAN AMERICANS; AGED; BODY MASS INDEX; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); OBESITY; ODDS RATIO; POSTMENOPAUSE; PROGESTINS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; RISK; UNITED STATES; WOMEN'S HEALTH;

EID: 84961054586     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv327     Document Type: Article

References (32)

1. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
2. Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
3. Chlebowski RT, Hendrix SL, Langer RD, et al.; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253.
4. Chlebowski RT, Anderson GL, Gass M, et al.; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
5. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
6. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy: The Women's Health Initiative randomized trial. JAMA. 2006;242:1048-1063.
7. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
8. Chlebowski RT, Anderson GL. Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012;104(7):517-527.
9. Harlid S, Butt S, Ivarsson MI, et al. Interactive effect of genetic susceptibility with height, body mass index, and hormone replacement therapy on the risk of breast cancer. BMC Womens Health. 2012;12:17.
10. Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013;105(18):1365-1372.
11. Méplan C, Dragsted LO, Ravn-Haren G, Tjønneland A, Vogel U, Hesketh J. Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer risk. PLoS ONE. 2013;8(9):e73316.
12. Obazee O, Justenhoven C, Winter S, et al. Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1-937-G variant. Breast Cancer Res Treat. 2013;138(2):543-548.
13. Cui Y, Deming-Halverson SL, Beeghly-Fadiel A, et al. Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk. Clin Cancer Res. 2014;20(5):1169-1178.
14. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-1059.
15. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283(4):485-491.
16. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328-332.
17. Banks E, Canfell K, Reeves G. HRT and breast cancer: recent findings in the context of the evidence to date. Womens Health (Lond Engl). 2008;4(5):427-431.
18. Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012;14(3):R76.
19. Campbell Jenkins BW, Addison C, Wilson G, et al. Association of the joint effect of menopause and hormone replacement therapy and cancer in African American women: the Jackson Heart Study. Int J Environ Res Public Health. 2011;8(6):2491-2504.
20. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.
21. Beral V, Reeves G, Bull D, Green J; Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296-305.
22. Segars JH, Parrott EC, Nagel JD, et al. Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations. Hum Reprod Update. 2014;20(3):309-333.
23. Larson CA. Prophylactic bilateral oophorectomy at time of hysterectomy for women at low risk: acog revises practice guidelines for ovarian cancer screening in low-risk women. Curr Oncol. 2014;21(1):9-12.
24. Weitzel JN, Buys SS, Sherman WH, et al. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res. 2007;13(2 Pt 1):654-658.
25. Benetti-Pinto CL, Brancalion MF, Assis LH, et al. Mammographic breast density in women with premature ovarian failure: a prospective analysis. Menopause. 2014;21(9):933-937.
26. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005;97(6):439-448.
27. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
28. Sineshaw HM, Gaudet M, Ward EM, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). Breast Cancer Res Treat. 2014;145(3):753-763.
29. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18(6):883-893.
30. Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med. 2006;144(8):541-553.
31. Sturtz LA, Melley J, Mamula K, Shriver CD, Ellsworth RE. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer. BMC Cancer. 2014;14:62.
32. Livaudais JC, Lacroix A, Chlebowski RT, et al. Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev. 2013;22(3):365-373.